Leg­end CEO spells out path to $5B in sales for mul­ti­ple myelo­ma CAR-T ther­a­py Carvyk­ti

Ap­proved in Feb­ru­ary as a fifth-line treat­ment for adults with re­lapsed or re­frac­to­ry mul­ti­ple myelo­ma, J&J and Leg­end’s CAR-T ther­a­py Carvyk­ti may not have start­ed out of the gate with a block­buster niche, pulling in just $55 mil­lion in its first quar­ter.

But just wait, Leg­end CEO Ying Huang ex­plained at a Jef­feries event in Lon­don this week.

Over the next three to four years, ac­cord­ing to a Jef­feries an­a­lyst note from this morn­ing, Huang said they are gear­ing up for a ma­jor man­u­fac­tur­ing over­haul that will al­low the com­pa­nies to pull in more than $5 bil­lion from Carvyk­ti, the sec­ond BC­MA CAR-T ap­proved by the FDA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER